Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs
- 20 February 2020
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 16 (3) , 240-249
Abstract
Cholinesterase inhibitors, the current frontline symptomatic treatment for Alzheimer’s disease (AD), are associated with low efficacy and adverse effects. M1 muscarinic acetylcholine receptors (M1 mAChRs) represent a potential alternate therapeutic target; however, drug discovery programs focused on this G protein-coupled receptor (GPCR) have failed, largely due to cholinergic adverse responses. Employing novel chemogenetic and phosphorylation-deficient, G protein-biased, mouse models, paired with a toolbox of probe molecules, we establish previously unappreciated pharmacologically targetable M1 mAChR neurological processes, including anxiety-like behaviors and hyper-locomotion. By mapping the upstream signaling pathways regulating these responses, we determine the importance of receptor phosphorylation-dependent signaling in driving clinically relevant outcomes and in controlling adverse effects including ‘epileptic-like’ seizures. We conclude that M1 mAChR ligands that promote receptor phosphorylation-dependent signaling would protect against cholinergic adverse effects in addition to driving beneficial responses such as learning and memory and anxiolytic behavior relevant for the treatment of AD.Keywords
Funding Information
- RCUK | Medical Research Council (MR/P019366/1)
- RCUK | Medical Research Council (MR/P019366/1)
- Wellcome Trust (201529/Z/16/Z)
- Alzheimer’s Research UK (PPG2017B-005)
This publication has 55 references indexed in Scilit:
- Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial OutcomesMolecular Pharmacology, 2018
- M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognitionNeuropsychopharmacology, 2018
- M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory lossJournal of Clinical Investigation, 2016
- Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse ModelNeuropsychopharmacology, 2015
- Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal ModelsJournal of Neuroscience, 2012
- NovelN-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1mAChR AgonistsACS Medicinal Chemistry Letters, 2010
- A Selective Allosteric Potentiator of the M1Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal LearningJournal of Neuroscience, 2009
- Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trialThe Lancet, 2004
- Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer DiseaseArchives of Neurology, 1997
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982